SCOTUS ruling on confidential sales: lawyers comment
A decision by the US Supreme Court yesterday will mean no change to the long-standing rules that apply to the “on-sale” bar, but may reduce the incentive for inventors to carry out confidential sales of their inventions, lawyers have told WIPR.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 January 2019 Companies that sell their inventions to third parties under confidential agreements may still end up invalidating their own patents based on the “on-sale” provision, the US Supreme Court said today.
4 December 2018 The US Supreme Court will today hear a patent dispute between Helsinn Healthcare and Teva Pharmaceuticals, with lawyers telling WIPR that the probable reversal in the case will have a wide-ranging impact.